Yumanity Therapeutics and Proteostasis Therapeutics Inc. announced that the companies have entered into a definitive merger agreement. The combined company, operating under the name Yumanity Therapeutics Inc., will leverage a common scientific expertise in the area of protein misfolding to advance Yumanity's pipeline of innovative, disease-modifying programs for neurodegenerative diseases. Following completion of the merger, the Yumanity Board of Directors will be expanded to nine persons to include the appointment of two current Proteostasis directors. The existing Yumanity Directors will continue to serve in their current positions and Dr. Coles will remain as chairperson. Upon the anticipated closing of the merger between PTI and Yumanity, Richard Peters, M.D., Ph.D., President and Director of Yumanity, will become President and Director of the combined company.